ProfileGDS5678 / 1417416_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 32% 30% 31% 31% 33% 31% 35% 32% 31% 30% 49% 31% 31% 38% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7677732
GSM967853U87-EV human glioblastoma xenograft - Control 22.6813330
GSM967854U87-EV human glioblastoma xenograft - Control 32.7130131
GSM967855U87-EV human glioblastoma xenograft - Control 42.6493631
GSM967856U87-EV human glioblastoma xenograft - Control 52.7041633
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7855431
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8497535
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7104832
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6719431
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6796130
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1747549
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6656931
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7121331
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8717738